Last reviewed · How we verify
Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
Approved treatments
- Bavencio · Merck KGaA
Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Bavencio · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy patent landscape — cliff calendar, originator estates, attackable patents
- Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy treatment landscape brief
- Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy treatment updates RSS
Frequently asked questions about Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
What drugs treat Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy?
Tracked treatments include Bavencio.
What is the treatment for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy?
Standard treatment for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy includes Bavencio. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy patent cliff · Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy CI report
- Treatment: Bavencio · Merck KGaA
- Treatment: Bavencio · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing